GlycoMimetics, Inc.

GlycoMimetics, Inc.
Investor Relations Department
9708 Medical Center Drive
Rockville, MD 20860
United States

Visit IR website
Sign-up for email alerts

NASDAQ: GLYC	
Last Trade:	5.56
Trade Time:	2:21 PM ET 03/30/2017
Change:	-0.12 (2.025%)
Day Range	5.47 - 5.75
52-Week Range	5.34 - 9.25
Volume	9,673

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow's breakthrough treatments.

GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company's inception in 2003, we have developed a robust, diver... (more)

Stock Performance

Press Releases [View all]

03/13/2017
GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors

03/07/2017
GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271

03/01/2017
GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017

03/01/2017
GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results

02/28/2017
GlycoMimetics to Present at Cowen 37th Annual Health Care Conference

Financials [View all]

Fourth Quarter Financial Results

03/01/2017
Annual Report (10-K)

04/11/2016
Proxy Statement (DEF 14A)

11/04/2016
Quarterly Report (10-Q)

08/04/2016
Quarterly Report (10-Q)

05/04/2016
Quarterly Report (10-Q)